摘要
血小板减少症是妇科恶性肿瘤患者在放化疗过程中常见的不良反应之一,是临床需要密切关注的重点,其可导致化疗药物治疗剂量降低,规律治疗进程受阻,增加患者出血风险,对疾病产生严重影响,严重时可能导致患者死亡。为进一步优化临床用药实践,本共识基于坚实的循证证据,明确妇科恶性肿瘤放化疗相关血小板减少症的预防及治疗策略,并确立了相应的临床路径及合适的给药方式。同时,本共识评估了促血小板生成药物在妇科恶性肿瘤放化疗过程中应用的有效性及安全性,旨在形成妇科恶性肿瘤放化疗相关血小板减少症规范化管理的中国专家共识。
Thrombocytopenia is one of the common adverse reactions in gynecological malignant tumor patients undergoing radiotherapy and chemotherapy,and it is the focus that clinicians need to pay close attention to.It can lead to the reduction of therapeutic dose,the obstruction of regular treatment process,the increase of bleeding risk of patients,and the serious impact of the disease,which can lead to death in severe cases.In order to further optimize clinical medication practice,this consensus,based on solid evidence-based evidence,defines prevention and treatment strategies for chemoradiationrelated thrombocytopenia in gynecological malignant tumors,and establishes corresponding clinical pathways and appropriate administration modalities.At the same time,this consensus evaluates the effectiveness and safety of the application of thrombopoietic drugs in the course of chemoradiotherapy for gynecological malignant tumors,and aims to form a Chinese expert consensus on the standardized management of chemoradiotherapy-related thrombocytopenia for gyneco-logical malignant tumors.
出处
《癌症进展》
2024年第19期2089-2095,共7页
Oncology Progress
基金
辽宁省应用基础研究计划项目(2022JH2/101300039)
2022年沈阳市科技计划项目(22-321-33-08)
沈阳市科技局2023年助力中国医科大学高质量发展专项(23-506-3-01-10)。
关键词
妇科恶性肿瘤
放化疗
血小板减少症
专家共识
gynecological malignant tumor
chemoradiotherapy
thrombocytopenia
expert consensus
作者简介
通信作者:张颐,邮箱:syzi@163.com;通信作者:王建东,邮箱:wangjiandongxy@hotmail.com;通信作者:张师前,邮箱:r370112@126.com。
